HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carrasquillo, J. A. Articles by Larson, S. M. Search for Related Content PubMed PubMed Citation Articles by Carrasquillo, J. A. Articles by Larson, S. M.

Indium-111 T101 Monoclonal Antibody is Superior to Iodine-131 T101 in Imaging of Cutaneous T-Cell Lymphoma

Departments of Nuclear Medicine, Clinical Center, National Cancer Institute-Navy Medical Oncology Branch; National Institutes of Health, Bethesda
Clinical Oncology and Biologic Response Modifiers Programs, National Cancer Institute, Frederick, Maryland

Correspondence: For reprints contact: Jorge A. Carrasquillo, MD, National Institutes of Health, Dept. of Nuclear Medicine, 9000 Rockville Pike, 10/1C-401, Bethesda, MD 20892.

ABSTRACT

We have reported that [¹¹¹In]T101 is highly effective in the detection of cutaneous T-cell lymphoma (CTCL) in nodal and cutaneous (erythroderma and tumor) sites. This study compares the biodistribution of [¹³¹I]T101 (1 to 7.1 mg, 2 mCi) in four patients with CTCL; two of these patients also received [¹¹¹In]T101 (1 mg, 5 mCi). There was rapid clearance of [¹³¹I]T101 from whole-body, spleen, liver, and bone marrow, with evidence of loss of ¹³¹I tracer from the T101. Lymph node uptake was minimal in three of four patients, and there was no localization in skin lesions. This contrasted with ¹¹¹In]T101 where there was prolonged retention of activity in these organs and excellent uptake in skin tumors, erythroderma, and lymph nodes. The study showed that [¹³¹I]T101 was suboptimal for imaging CTCL patients and demonstrates that the isotope or labeling method can dramatically alter the apparent biodistribution and tumor targeting of a given monoclonal antibody.

FOOTNOTES

^* Present address: Div. of Medical Oncology, Box B171, University of Colorado Health Science Center, 4200 E. 9th Ave., Denver, CO 80262.

This article has been cited by other articles:

				A. H. Brouwers, W. C. A. M. Buijs, E. Oosterwijk, O. C. Boerman, C. Mala, P. H. M. De Mulder, F. H. M. Corstens, P. F. A. Mulders, and W. J. G. Oyen Targeting of Metastatic Renal Cell Carcinoma with the Chimeric Monoclonal Antibody G250 Labeled with 131I or 111In: An Intrapatient Comparison Clin. Cancer Res., September 1, 2003; 9(10): 3953S - 3960. [Abstract] [Full Text] [PDF]

				Z. Yao, K. Garmestani, K. J. Wong, L. S. Park, E. Dadachova, A. Yordanov, T. A. Waldmann, W. C. Eckelman, C. H. Paik, and J. A. Carrasquillo Comparative Cellular Catabolism and Retention of Astatine-, Bismuth-, and Lead-Radiolabeled Internalizing Monoclonal Antibody J. Nucl. Med., October 1, 2001; 42(10): 1538 - 1544. [Abstract] [Full Text] [PDF]

				F.-T. Lee, A. Rigopoulos, C. Hall, K. Clarke, S. H. Cody, F. E. Smyth, Z. Liu, M. W. Brechbiel, N. Hanai, E. C. Nice, et al. Specific Localization, Gamma Camera Imaging, and Intracellular Trafficking of Radiolabelled Chimeric Anti-GD3 Ganglioside Monoclonal Antibody KM871 in SK-MEL-28 Melanoma Xenografts Cancer Res., June 1, 2001; 61(11): 4474 - 4482. [Abstract] [Full Text] [PDF]

				L. H. Pai-Scherf, J. A. Carrasquillo, C. Paik, O. Gansow, M. Whatley, D. Pearson, K. Webber, M. Hamilton, C. Allegra, M. Brechbiel, et al. Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3 Clin. Cancer Res., May 1, 2000; 6(5): 1720 - 1730. [Abstract] [Full Text]